Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Yingshuai Lv"'
Autor:
Tianhao Ren, Ju Huang, Wei Sun, Guangze Wang, Yuwen Wu, Zewei Jiang, Yingshuai Lv, Guang Wu, Jiawei Cao, Min Liu, Haihua Gu
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2023)
Aims: Ferroptosis plays important roles in tumorigenesis and cancer therapy. Zoledronic acid is known to inhibit the activity of farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway. We examined whether zoledronic acid can inhibit
Externí odkaz:
https://doaj.org/article/7620ef81f23f4d3fa4699cc27da90921
Autor:
Jiawei Cao, Du Wu, Guang Wu, Yaqi Wang, Tianhao Ren, Yang Wang, Yingshuai Lv, Wei Sun, Jieyi Wang, Changrui Qian, Licai He, Kaiyan Yang, Hongzhi Li, Haihua Gu
Publikováno v:
Cell Death and Disease, Vol 12, Iss 6, Pp 1-13 (2021)
Abstract Although endocrine therapies targeting estrogen receptor α (ERα) are effective in managing ER positive (+) breast cancer, many patients have primary resistance or develop resistance to endocrine therapies. In addition, ER+ breast cancer wi
Externí odkaz:
https://doaj.org/article/ced7b7eae0324dcab619cbb26ff259c8
Autor:
Changrui Qian, Yaqi Wang, Kaiyan Yang, Tianhao Ren, Hongzhi Li, Jiawei Cao, Yingshuai Lv, Haihua Gu, Jieyi Wang, Yang Wang, Du Wu, Guang Wu, Licai He, Wei Sun
Publikováno v:
Cell Death and Disease, Vol 12, Iss 6, Pp 1-13 (2021)
Cell Death & Disease
Cell Death & Disease
Although endocrine therapies targeting estrogen receptor α (ERα) are effective in managing ER positive (+) breast cancer, many patients have primary resistance or develop resistance to endocrine therapies. In addition, ER+ breast cancer with PIK3CA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb749c73a93679b259beb2a0355fe12b
https://doaj.org/article/ced7b7eae0324dcab619cbb26ff259c8
https://doaj.org/article/ced7b7eae0324dcab619cbb26ff259c8
Autor:
Yuxin Qiu, Xiaoxia Wang, Lingjie Zhao, Jiawei Cao, Guang Wu, Lan Li, Hongzhi Li, Tianhao Ren, Haihua Gu, Wei Sun, Hongqun Tao, Yingshuai Lv, Mengnan Liu, Licai He
Publikováno v:
Acta biochimica et biophysica Sinica. 53(12)
Mucin 1 (MUC1) has been regarded as an ideal target for cancer treatment, since it is overexpressed in a variety of different cancers including the majority of breast cancer. However, there are still no approved monoclonal antibody drugs targeting MU
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::178af28613c6ce4341597a9e0fa8c9c6
https://pubmed.ncbi.nlm.nih.gov/34586349
https://pubmed.ncbi.nlm.nih.gov/34586349